Tamoxifen-encapsulated vesicular systems: Cytotoxicity evaluation in human epidermal keratinocyte cell line

Drug Development and Industrial Pharmacy

Volumn 36, Issue 3, 2010, Pages 350-354

  Bhatia, Amit ^a   Singh, Bhupinder ^a   Bhushan, Shashi ^b   Katare, Om Prakash ^a  

^a PANJAB UNIVERSITY   (India)

^b CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

HEK001; Liposome; MTT assay; Phospholipid; Skin; Topical

Indexed keywords

LIPOSOME; TAMOXIFEN;

ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CYTOTOXICITY; DRUG FORMULATION; DRUG POTENCY; ENCAPSULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE;

EID: 77249156842     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903173549     Document Type: Article

References (23)

1. Jordan VC, Brodie AM. (2007). Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids, 72:7-25.
2. Robertson JF. (2002). Current role of endocrine therapy in the management of breast cancer. Breast Cancer, 9:276-281
3. Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. (2005). Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: A decision analysis. J Clin Oncol, 23:5178-5187
4. Gradishar WJ. (2003). Adjuvant systemic therapy of early stage breast cancer. Curr Treat Options Oncol, 4:141-150
5. Boyd AS, King LE Jr. (1999). Tamoxifen-induced remission of psoriasis. J Am Acad Dermatol, 41:887-889
6. Stevens HP, Ostlere LS, Black CM, Jacobs HS, Rustin MHA. (1993). Cyclical psoriatic arthritis responding to anti-oestrogen therapy. Br J Dermatol, 129:458-460
7. Ferrari VD, Jirillo A. (1996). Psoriasis and tamoxifen therapy: A case report. Tumori, 82:262-263
8. Hu D, Hughes MA, Cherry GW. (1998). Topical tamoxifen-a potential therapeutic regime in treating excessive dermal scarring? Br J Plast Surg, 51:462-469
9. Kanda N, Watanabe S. (2003). 17-beta-estradiol inhibits the production of interferon-induced protein of 10 kDa by human keratinocytes. J Invest Dermatol, 120:411-419
10. Strickland C. (2002). Benefits of tamoxifen for breast cancer prevention do not always outweigh overall risks. J Fam Pract, 51:1016.
11. Varras M, Akrivis Ch. (2003). Large endometrial polyp with sarcomatous stromal components following long-term tamoxifen treatment for breast cancer: A case report and review of the literature. Eur J Gynaecol Oncol, 24:565-568
12. Bergh J. (2003). Breast-cancer prevention: Is the risk-benefit ratio in favour of tamoxifen? Lancet, 9379:183-184
13. Bjarnason NH, Hitz M, Jorgensen NR, Vestergaard P. (2008). Adverse bone effects during pharmacological breast cancer therapy. Acta Oncol, 47:747-754
14. Bernstein PS, DellaCroce JT. (2007). Diagnostic and therapeutic challenges. Tamoxifen toxicity. Retina, 27:982-988
15. Katare OP, Sinha VR, Bhatia A, Kumar R, Gupta S. (2006). Synergistic liposomal tamoxifen composition for topical application and method of preparing thereof. International patent publication PCT No.: WO 2006/001035 A2.
16. Bhatia A, Kumar R, Katare OP. (2004). Tamoxifen entrapped topical liposomes: Development, characterization and in-vitro evaluation. J Pharm Pharm Sci, 7:252-259
17. van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG, Langenhuijsen MM. (1994). A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods, 174:311-320
18. Bhushan S, Kumar A, Malik F, Andotra SS, Sethi VK, Kaur IP, et al. (2007). A triterpenediol from Boswellia serrata induces apoptosis through both the intrinsic and extrinsic apoptotic pathways in human leukemia HL-60 cells. Apoptosis, 12:1911-1926
19. Batzri S, Korn ED. (1975). Interaction of phospholipid vesicles with cells. J Cell Biol, 66:621-634
20. Ishimoto Y, Ohashi K, Mizuno K, Nakano T. (2000). Promotion of the uptake of PS liposomes and apoptotic cells by a product of growth arrest-specific gene, gas6. J Biochem, 127:411-417
21. Peek LJ, Middaugh CR, Berkland C. (2008). Nanotechnology in vaccine delivery. Adv Drug Deliv Rev, 60:915-928
22. Manconi M, Isola R, Falchi AM, Sinico C, Fadda AM. (2007). Intracellular distribution of fluorescent probes delivered by vesicles of different lipidic composition. Colloids Surf B Biointerfaces, 57:143-151
23. Karanth H, Murthy RS. (2007). pH-sensitive liposomes- principle and application in cancer therapy. J Pharm Pharmacol, 59:469-483